Why Insulet’s latest earnings and outlook matter for investors

Insulet (PODD) recently reported second quarter 2026 results that showed higher sales, revenue and net income compared with a year earlier, alongside stronger earnings per share from continuing operations.

The company also issued new guidance that points to total GAAP revenue growth expectations in the high teens for the upcoming quarter and just above 20% for the full 2026 year.

Despite the upbeat second quarter results and raised revenue outlook, Insulet’s share price return has been weak, with the stock down 10.28% over 30 days and 48.85% year to date, and the 1 year total shareholder return down 53.27%. This pattern suggests recent earnings strength has not yet shifted overall sentiment. However, the 1 day share price return of 1.30% hints at some interest returning around the latest update.

If Insulet’s recent move has you reassessing growth ideas in healthcare, this can be a useful moment to scan other opportunities in medical technology and data driven care through our 43 healthcare AI stocks.

Insulet’s earnings profile and guidance look strong on paper, yet the share price has fallen sharply over the past year. Is this latest move a delayed reaction to the business, or a reflection of shifting sentiment ahead of the next leg in valuation work?

Most Popular Narrative: 38.6% Undervalued

Insulet’s most followed valuation narrative places fair value at about $235.54 per share, which is well above the last close of $144.70. That gap raises clear questions about what assumptions are doing the heavy lifting in the story.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Curious what turns that Omnipod 5 growth story into a fair value almost 40% above today’s price? The narrative leans on compounding revenue, rising margins, and a future earnings multiple that needs to compress yet still support a higher valuation. The full set of assumptions connects those moving parts in a way that is not obvious from the headline numbers alone.

Result: Fair Value of $235.54 (UNDERVALUED)

However, Insulet’s Omnipod focus, ongoing recalls and related class action cases could still unsettle confidence and weaken the foundations of that undervalued narrative.

Next Steps

With so much attention on whether Insulet is mispriced, this is a good moment to act quickly and weigh the numbers for yourself through the 3 key rewards.

Looking for more investment ideas beyond Insulet?

If Insulet has you thinking differently about risk, reward and timing, do not stop here. Broaden your watchlist today so you are not reacting after the crowd moves.

• Target potential mispricings early by scanning companies that stand out on quality and value using the 49 high quality undervalued stocks.
• Strengthen your core holdings by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (50 results).
• Spot underfollowed stories that still show solid fundamentals with the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.